HR7868

The 'Expanding Support for Living Donors Act of 2026' (HR7868) amends the Public Health Service Act to expand the Living Organ Donation Reimbursement Program. The bill removes income-based eligibility limits for reimbursement for individuals with household incomes at or below 700 percent of the poverty line. It also increases the maximum reimbursement amount for qualifying expenses to $10,000 for fiscal year 2027, with annual adjustments based on the Consumer Price Index. This directly increases the financial viability of living organ donation for a broader segment of the population, leading to a higher number of available organs for transplant. Funding for this program flows through grant awards to recipients who then reimburse donating individuals. The bill does not specify new appropriations but modifies the existing program's parameters. The increased reimbursement and expanded eligibility will lead to more organ donation procedures. This benefits the entire organ transplant ecosystem, including hospitals and transplant centers. The bill does not identify specific companies that will receive direct funding or contracts, as the reimbursement is for individuals, not corporations. Historically, legislation that increases access to healthcare services or expands reimbursement for medical procedures tends to be bullish for the healthcare sector. For example, the Affordable Care Act (ACA) in 2010 expanded health insurance coverage, which led to increased utilization of healthcare services and generally positive market sentiment for healthcare providers and medical device companies. While not directly comparable in scope, this bill similarly expands access to a specific medical procedure by reducing financial barriers. There is no direct historical precedent for a bill specifically increasing living organ donor reimbursement on this scale, but the principle of increased access driving demand holds. Specific winners are hospitals and transplant centers that perform organ transplants. Companies involved in organ preservation, transport, and post-transplant care will also see increased activity. However, the bill does not name specific publicly traded companies that directly benefit from individual donor reimbursement. The impact is diffused across the healthcare system. The bill was introduced by Rep. DelBene (D-WA-1) and has two cosponsors, indicating moderate legislative momentum. It has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The next step is committee consideration, which could include hearings and markups. Passage through these committees is necessary before a floor vote. Timeline: The bill was introduced on March 9, 2026. Committee consideration will occur in the coming months. If passed, the changes to reimbursement amounts would take effect in fiscal year 2027.